Mirum Pharmaceuticals, Inc. Available-for-sale Securities, Gross Realized Losses
Mirum Pharmaceuticals, Inc. (MIRM) reported Available-for-sale Securities, Gross Realized Losses of $0 for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-28.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses · last filed 2019-08-28
- 2019-06-30: Available-for-sale Securities, Gross Realized Losses 6 month $0.00.
| Period end | Available-for-sale Securities, Gross Realized Losses 6 month |
|---|---|
| 2019-06-30 | $0.00 10-Q · filed 2019-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |